We invite you to watch the recording of our recent webinar focused on Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy. This webinar recording is intended for all urology and oncology physicians and staff.
What is Enzalutamide?
Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy. (1)
What else is covered in the video?
(1) "Enzalutamide in Metastatic Prostate Cancer before Chemotherapy." National Center for Biotechnology Information. U.S. National Library of Medicine, 31 July 2014. Web. 7 Aug. 2014. <http://www.ncbi.nlm.nih.gov/pubmed/24881730>.